Lung Cancer Clinical Trials in Miami, FL

View the best 10 lung cancer medical studies in Miami, Florida. Access promising new therapies by applying to a Miami-based Lung Cancer clinical trial.

Trials in Miami, Florida

Here are the top 10 medical studies for lung cancer in Miami, Florida

Phase 3 comparator arm +3 More

Chemotherapy

Recruiting1 awardPhase 2 & 3

This trial tests two drugs, MRTX849 and pembrolizumab, in patients with advanced lung cancer who have a specific genetic mutation. MRTX849 targets the mutation to stop cancer growth, while pembrolizumab boosts the immune system to fight the cancer. The study aims to see how well these treatments work alone and together.

HLX10

Monoclonal Antibodies

Recruiting3 awardsPhase 3

This trial is testing two different treatment combinations for patients with extensive-stage small cell lung cancer who have not received any prior treatment. One group will receive a new drug called Serplulimab along with standard chemotherapy, while the other group will receive an existing drug called Atezolizumab with the same chemotherapy. Both immunotherapy drugs aim to help the immune system fight cancer, and the chemotherapy drugs work by killing cancer cells. Atezolizumab has been shown to improve survival in small-cell lung cancer when combined with chemotherapy, changing the standard first-line therapy.

LN-145

CAR T-cell Therapy

Recruiting1 awardPhase 2

This trial tests LN-145, a treatment using a patient's own lab-prepared immune cells, in patients with advanced lung cancer that has spread. The process includes reducing existing immune cells, infusing enhanced ones, and boosting their activity.

Lutetium Lu 177 Dotatate

Radioactive Drug

Recruiting1 awardPhase 2

This trial studies the effect of lutetium Lu 177 dotatate in patients with advanced bronchial neuroendocrine tumors. Lutetium Lu 177 dotatate targets cancer cells with radiation, aiming to kill or shrink them while sparing healthy cells. The goal is to see if it works better than the usual treatment. Everolimus has been shown to help patients with various types of neuroendocrine tumors.

ELI-002 7P

Recruiting1 awardPhase 1 & 2

This trial is testing a new treatment called ELI-002 7P for patients with specific types of cancer. The treatment helps the immune system recognize and attack these cancer cells. ELI-002 7P targets mutations that are common in various cancers and have been studied for their role in tumor growth and resistance to treatments.

Dyspnea Intervention

Behavioral Intervention

Recruiting1 award4 criteria

This trial aims to test a new intervention called BREEZE+ to help patients with advanced lung cancer manage their breathlessness. The intervention includes brief nurse-delivered sessions and a digital health app to teach

Entrectinib +3 More

Procedure

Recruiting2 awardsPhase 3

This trial is testing different treatments to see how well they work and how safe they are. It focuses on patients with advanced lung cancer that cannot be removed by surgery and have specific biological markers. The goal is to find out if these treatments can stop the cancer from growing or spreading and improve patients' health.

MRTX849 (Adagrasib)

Small Molecule Drug

Recruiting2 awardsPhase 3

This trial is testing a new drug called adagrasib against an existing chemotherapy drug, docetaxel. It focuses on patients with advanced lung cancer who have a specific genetic mutation (KRAS G12C) and have already had treatment. The new drug aims to block this mutation in cancer cells to stop their growth.

Stereotactic Body Radiation Therapy +1 More

Radiation

Recruiting1 awardPhase 2

This trial is testing whether combining the drug durvalumab with a precise radiation treatment is more effective for early-stage lung cancer patients than using the radiation treatment alone. Durvalumab has shown promise in improving survival rates in advanced lung cancer patients and is being tested in various combinations, including with radiation therapy.

Treatment

Recruiting1 award4 criteria

This trial is testing a blood test to see if it can detect lung cancer early in high-risk individuals. Blood samples will be collected from participants who are getting a routine CT scan for lung cancer screening.

Popular Filters

Phase 3 Trials

Anti-microtubule agent

DS-1062a vs Docetaxel for Lung Cancer

Recruiting2 awardsPhase 3

Hollywood, Florida

This trial will compare the effectiveness of DS-1062a to the current standard of care drug, docetaxel, in treating lung cancer.

Chemotherapy

Adagrasib + Pembrolizumab for Lung Cancer

Recruiting1 awardPhase 2 & 3

Miami, Florida

This trial tests two drugs, MRTX849 and pembrolizumab, in patients with advanced lung cancer who have a specific genetic mutation. MRTX849 targets the mutation to stop cancer growth, while pembrolizumab boosts the immune system to fight the cancer. The study aims to see how well these treatments work alone and together.

Alkylating agents

Pembrolizumab SC vs IV for Lung Cancer

Recruiting2 awardsPhase 3

Hollywood, Florida

This trial is testing a new way to give the cancer drug pembrolizumab as an injection under the skin for people with advanced lung cancer. The goal is to see if this method works as well as the traditional IV method. The study will also check if it is safe and effective when used with standard chemotherapy.

Platinum-containing Compound

Radiation + Immunotherapy for Non-Small Cell Lung Cancer

Recruiting1 awardPhase 2 & 3

Savannah, Georgia

This trial is testing the addition of radiation therapy to the usual immunotherapy (with or without chemotherapy) treatment for patients with non-small cell lung cancer that has spread to nearby tissue or lymph nodes (advanced) or has spread to other places in the body (metastatic) and who are also negative for a molecular marker called PD-L1.

Anti-tumor antibiotic

Telisotuzumab Vedotin vs. Docetaxel for Non-Small Cell Lung Cancer

Recruiting2 awardsPhase 3

Tamarac, Florida

This trial is testing a new drug called telisotuzumab vedotin to see if it can treat a specific type of lung cancer better than an existing drug. The study focuses on adults whose lung cancer has not responded to previous treatments. The new drug targets and kills cancer cells by attaching to a specific protein on their surface.

Radiation Therapy

Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for Brain Metastasis from Lung Cancer

Recruiting2 awardsPhase 3

Miami, Florida

This trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus for the treatment of small cell lung cancer that has spread to the brain.

Trials With No Placebo

Antibody-drug conjugate

CAB-AXL-ADC + PD-1 Inhibitor for Lung Cancer

Recruiting1 awardPhase 2

West Palm Beach, Florida

This trial is testing a new cancer drug to see if it is safe and effective for patients with non-small cell lung cancer.

Radioactive Drug

Lutetium Lu 177 Dotatate for Lung Carcinoid Tumor

Recruiting1 awardPhase 2

Miami, Florida

This trial studies the effect of lutetium Lu 177 dotatate in patients with advanced bronchial neuroendocrine tumors. Lutetium Lu 177 dotatate targets cancer cells with radiation, aiming to kill or shrink them while sparing healthy cells. The goal is to see if it works better than the usual treatment. Everolimus has been shown to help patients with various types of neuroendocrine tumors.

Anti-microtubule agent

DS-1062a vs Docetaxel for Lung Cancer

Recruiting2 awardsPhase 3

Hollywood, Florida

This trial will compare the effectiveness of DS-1062a to the current standard of care drug, docetaxel, in treating lung cancer.

Targeted Therapy

Sotorasib for Non-Small Cell Lung Cancer

Recruiting2 awardsPhase 2

Birmingham, Alabama

This trial studies the effect of AMG 510 in treating patients with KRAS G12C mutated non-squamous non-small cell lung cancer.

Monoclonal Antibodies

Patritumab Deruxtecan for Non-Small Cell Lung Cancer

Recruiting1 awardPhase 2

Pembroke Pines, Florida

This trial is testing a new drug called patritumab deruxtecan for patients with advanced lung cancer who have specific genetic mutations and have not responded to other treatments. The drug targets cancer cells specifically and delivers chemotherapy directly to them.

CAR T-cell Therapy

Autologous LN-145 for Lung Cancer

Recruiting1 awardPhase 2

Miami, Florida

This trial tests LN-145, a treatment using a patient's own lab-prepared immune cells, in patients with advanced lung cancer that has spread. The process includes reducing existing immune cells, infusing enhanced ones, and boosting their activity.

View More Related Trials

Frequently Asked Questions

Do I need insurance to participate in a trial?

Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).

Is there any support for travel costs?

Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.

Will I know what medication I am taking?

This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.

How long do clinical trials last?

Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.

Do you verify all the trials on your website?

All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.

How quickly will I hear back from a clinical trial?

Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.